Neurotech International Archives | Page 2 of 6 | Cannabiz

PK study shows further promise for Neurotech paediatric CBDA drug

by Steve Jones June 3, 2025June 3, 2025

The first human pharmacokinetics study of Neurotech International’s broad-spectrum cannabinoid treatment, NTI164, has shown positive results […]

News in brief: Rua’s German stock shortage; Zelira’s finance deal; cultivator nets $1.4m; Neurotech exec steps down; ‘major milestone’ for Argent; Cann Group pharmacy deal

by Steve Jones and Martin Lane April 3, 2025April 3, 2025

News in brief: Cannabis Council Australia; Leafio; Neurotech

by cannabiz team February 13, 2025February 17, 2025

News in brief: InhaleRx; Hemp Pet; Neurotech International; Cann Group

by Martin Lane November 19, 2024April 11, 2025

News in brief: Israel anti-dumping measures; Neurotech International; NZ prescription data

by Martin Lane November 13, 2024April 11, 2025

Cannabis executive salaries: who earned what in FY24

by Steve Jones October 16, 2024October 15, 2025

US FDA rejects Neurotech application for orphan drug status

by Steve Jones October 8, 2024February 25, 2025

Neurotech seeks pharma partners for overseas drug development but will go it alone in Australia

by Steve Jones August 12, 2024August 12, 2024

Company news: ECS Botanics; Althea; InhaleRx; Neurotech International

by Martin Lane and Steve Jones July 10, 2024July 11, 2024

medical cannabis for children

Cannabinoid drug developer holds ‘positive’ talks with TGA as hopes rise of fast-tracking ARTG listing

by Steve Jones June 28, 2024June 28, 2024